Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8881 to 8887 of 8887 results

  1. Women inspiring inclusion in NICE guidance

    This International Women’s Day, we’re focusing on the invaluable contributions of 2 of the women who help shape our guidance through their independent voluntary committee roles. They talk to us about their involvement with NICE and what #InspireInclusion means to them.

  2. Risdiplam not recommend for treating spinal muscular atrophy

    NICE has today (2 June 2021) published draft guidance for which does not recommend risdiplam for treating the rare genetic disorder spinal muscular atrophy (SMA).

  3. NICE provides access to new treatment option for advanced breast cancer

    NICE has today (20 April 2021) published draft guidance recommending trastuzumab deruxtecan for use in the Cancer Drugs Fund (CDF).

  4. People with a rare form of blood cancer are set to benefit after NICE recommends new targeted therapy

    Hundreds of people with multiple myeloma could receive a new, targeted treatment recommended for use within the Cancer Drugs Fund today (Tuesday, 29 October).

  5. New treatment for cardiovascular disease could benefit millions

    Up to 2.1 million people with cardiovascular disease (CVD) could benefit from a new cholesterol target outlined in NICE guidance for the first time.

  6. Updated guideline recommends more treatment choices for menopause symptoms

    New evidence shows that cognitive behavioural therapy (CBT) can help reduce menopause symptoms including hot flushes and night sweats, depressive symptoms and problems sleeping NICE has said in its draft updated guideline on menopause published today (17 November 2023).

  7. NICE joins the shared commitment to public involvement in research

    Working alongside people and communities is an essential tool in helping to improve?the impact of our guidance and continuing to get the best care to people and communities, fast, while ensuring value for the taxpayer.